Efficacy and safety of the enzymatic mixture - Lipase, collagenase and hyaluronidase - In the treatment of moderate to severe submental fat: A prospective cohort study.

Collagenase Hyaluronidase Lipase Submental fat

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
29 Feb 2024
Historique:
received: 10 07 2023
revised: 30 01 2024
accepted: 01 02 2024
medline: 20 2 2024
pubmed: 20 2 2024
entrez: 20 2 2024
Statut: epublish

Résumé

To study the effect of the enzymatic mixture: Lipase, Collagenase and Hyaluronidase in the treatment of submental fat. A monocentric prospective cohort study including 10 female patients, aged between 18 and 65 years old, who received treatment for submental fat with a mixture of Lipase, Collagenase, and Hyaluronidase. The treatment protocol consisted of one treatment session every 21 days for a total of 3 sessions. In each session, 4 ml of the enzymatic mixture (1 ml of Collagenase GH PB20, 1 ml of Hyaluronidase PB 3000 and 2 ml of Lipase PB 500) + 2 ml of Lidocaine 2% were injected in the submental fat (SMF). Efficacy was assessed four weeks after the last session. Co-Primary Outcome was defined as the improvement of ≥ 1-point in Clinician-Reported and Patient-Reported Sub-mental Fat Rating Scales (CR-SMFRS and PR-SMFRS). Secondary Outcomes included score reductions in Patient-Reported Sub-mental Fat Impact Scale (PR-SMFIS), ≥10% reduction in submental fat pad thickness by ultrasound, and Subject Self-Rating Scale (SSRS) responses of 4, 5, or 6. The Co-Primary outcome was achieved in 9 out of 10 patients. A considerable reduction of 22.8% in the PR-SMFIS was observed. Furthermore, 9 out of 10 patients expressed overall satisfaction with the treatment. Submental fat reduction of more than 10% was observed in 9 out of 10 patients in neutral position and in all patients in flexed position. Adverse effects were only limited to local reactions. The enzymatic mixture of Lipase, Collagenase and Hyaluronidase is an effective and safe minimally-invasive method for the reduction of SMF that can be used alone or in conjunction with other treatment modalities.

Identifiants

pubmed: 38375282
doi: 10.1016/j.heliyon.2024.e25759
pii: S2405-8440(24)01790-0
pmc: PMC10875420
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e25759

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Rita Jabbour (R)

Dermatology Department, Hôtel-Dieu de France Hospital, Beirut, Lebanon.

Fadi Farah (F)

Radiology Department, Hôtel-Dieu de France Hospital, Beirut, Lebanon.

Farid Mallat (F)

Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Eddy Saad (E)

Internal Medicine Department, Hôtel-Dieu de France Hospital, Beirut, Lebanon.

Karl Semaan (K)

Internal Medicine Department, Hôtel-Dieu de France Hospital, Beirut, Lebanon.

Roger Haber (R)

Dermatology Department, University of Illinois, Chicago, USA.

Josiane Helou (J)

Dermatology Department, Hôtel-Dieu de France Hospital, Beirut, Lebanon.
Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Classifications MeSH